Show simple item record

dc.contributor.authorColas, RAen_US
dc.contributor.authorSouza, PRen_US
dc.contributor.authorWalker, MEen_US
dc.contributor.authorBurton, Men_US
dc.contributor.authorZasłona, Zen_US
dc.contributor.authorCurtis, AMen_US
dc.contributor.authorMarques, RMen_US
dc.contributor.authorDalli, Jen_US
dc.date.accessioned2019-02-05T09:57:27Z
dc.date.available2018-02-02en_US
dc.date.issued2018-03-16en_US
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/55164
dc.description.abstractRATIONALE: Diurnal mechanisms are central to regulating host responses. Recent studies uncovered a novel family of mediators termed as specialized proresolving mediators that terminate inflammation without interfering with the immune response. OBJECTIVE: Herein, we investigated the diurnal regulation of specialized proresolving mediators in humans and their role in controlling peripheral blood leukocyte and platelet activation. METHODS AND RESULTS: Using lipid mediator profiling and healthy volunteers, we found that plasma concentrations of n-3 docosapentaenoic acid-derived D-series resolvins (RvDn-3 DPA) were regulated in a diurnal manner. The production and regulation of these mediators was markedly altered in patients at risk of myocardial infarct. These changes were associated with decreased 5-lipoxygenase expression and activity, as well as increased systemic adenosine concentrations. We also found a significant negative correlation between plasma RvDn-3 DPA and markers of platelet, monocyte, and neutrophil activation, including CD63 and CD11b. Incubation of RvDn-3 DPA with peripheral blood from healthy volunteers and patients with cardiovascular disease significantly and dose-dependently decreased platelet and leukocyte activation. Furthermore, administration of RvD5n-3 DPA to ApoE-/- (apolipoprotein E deficient) mice significantly reduced platelet-leukocyte aggregates, vascular thromboxane B2 concentrations, and aortic lesions. CONCLUSIONS: These results demonstrate that peripheral blood RvDn-3 DPA are diurnally regulated in humans, and dysregulation in the production of these mediators may lead to cardiovascular disease.en_US
dc.description.sponsorshipSir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (grant number: 107613/Z/15/Z),en_US
dc.description.sponsorshipEuropean Research Council under the European Union’s Horizon 2020 research and innovation program (grant number: 677542),en_US
dc.description.sponsorshipBarts Charity (grant number: MGU0343en_US
dc.description.sponsorshipMedical Research Council Advance Course Masters (grant number: MR/J015741/1)en_US
dc.description.sponsorshipScience Foundation Ireland Starting Investigator Research Grant 13/SIRG/2130en_US
dc.description.sponsorshipWellcome Trust grant 101604/Z/13/Zen_US
dc.format.extent855 - 863en_US
dc.languageengen_US
dc.language.isoen_USen_US
dc.relation.ispartofCirc Resen_US
dc.rightsCreative Commons Attribution Non-Commercial License
dc.subjectadenosineen_US
dc.subjecteicosanoidsen_US
dc.subjectlipoxygenaseen_US
dc.subjectmonocyteen_US
dc.subjectneutrophilsen_US
dc.subjectplateletsen_US
dc.titleImpaired Production and Diurnal Regulation of Vascular RvDn-3 DPA Increase Systemic Inflammation and Cardiovascular Disease.en_US
dc.typeArticle
dc.rights.holder© 2018 The Authors.
dc.identifier.doi10.1161/CIRCRESAHA.117.312472en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/29437834en_US
pubs.issue6en_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume122en_US
dcterms.dateAccepted2018-02-02en_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record